Biofarm SA

Biofarm SA maintains a strong liquidity position, with a current ratio of 4.95 and cash and equivalents of RON 111.75 million, which is significantly higher than the median for its industry. The company's liquidity_fpt score indicates a low liquidity risk, supported by its high operating cash flow of RON 80.52 million and free cash flow of RON 75.26 million. In terms of profitability, Biofarm SA demonstrates a return on equity (ROE) of 18.35% and a return on assets (ROA) of 15.8%, both of which exceed the industry median for pharmaceutical companies. The company's operating income of RON 105.88 million and net income of RON 100.63 million reflect strong operational performance and efficient cost management. The company's revenue is primarily concentrated in Romania, with no disclosed international segments. While the input data does not provide a breakdown of geographic exposure, the absence of international operations suggests a high degree of revenue concentration in the domestic market, which could expose the company to local economic and regulatory risks. Looking ahead, the company's growth trajectory is expected to remain stable, with no significant changes in revenue or earnings projected for the next fiscal year. The capital expenditure of RON -14.67 million indicates a reduction in investment, which may signal a focus on maintaining current operations rather than expanding. The risk assessment for Biofarm SA indicates a low risk of dilution and no immediate liquidity concerns. The company's debt-to-equity ratio is 0.0, suggesting a conservative capital structure with no long-term debt obligations. This financial stability supports the company's ability to withstand economic downturns without the pressure of debt servicing. Recent filings and transcripts do not highlight any material events or strategic shifts. The company's primary shareholder, Societatea de Investitii Financiare Muntenia SA, has not disclosed any plans for restructuring or significant capital raising activities. Analysts have provided a consistent price target of RON 0.85, indicating a stable outlook for the stock.